Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium

References

• Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Annals of Oncology 2007; 18: 1425–1427.
   Google Scholar
• The UK Collaborative Group for HIV and STI Surveillance. Testing Times. HIV and Other Sexually Transmitted Infections in the United Kingdom: 2007. Health Protection Agency, Centre for Infections, LondonUK 2007
   Google Scholar
• Hulstaert F, Arbyn M, Huybrechts M, et al. Dépistage du cancer du col de l’utérus et recherche du papillomavirus humain (HPV). Health Technology Assessment (HTA). KCE report 38B. Centre fédéral d’expertise des soins de santé (KCE), BrusselsBelgium 2006.
   Google Scholar
• Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000. Cancer Incidence, Mortality and Prevalence Worldwide.IARC CancerBase No. 5, version 2.0. IARC Press, LyonFrance 2004.
   Google Scholar
• Von Krogh G. Management of anogenital warts (condylomata acuminata). European Journal of Dermatology 2001; 11: 598–603
   PubMed Web of Science ®Google Scholar
• Walboomers JMM, Jacobs MV, Manos M, et al. Human papillomavirus: a necessary cause of invasive cervical cancer world-wide. Journal of Pathology 1999; 189: 12–19
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348: 518–527
   PubMed Web of Science ®Google Scholar
• Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987; 1: 1247–1249
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Vol. 10. IARC Press, LyonFrance 2005
   Google Scholar
• Arbyn M, Van Oyen H. Cervical cancer screening in Belgium. European Journal of Cancer 2000; 36: 2191–2197
   Web of Science ®Google Scholar
• Arbyn M, Van Oyen H. Analysis of individual health insurance data pertaining to pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996–2000). Epidemiology, October 2004. Scientific Institute of Public Health, SIPH/EPI Report N 2004–021, BrusselsBelgium
   Google Scholar
• Fenton KA, Lowndes CM. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sexually Transmitted Infections 2004; 80: 255–263
   PubMed Web of Science ®Google Scholar
• Koutsky L. Epidemiology of genital human papillomavirus infection. American Journal of Medicine 1997; 102: 3–8
   PubMedGoogle Scholar
• Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. Journal of Infectious Diseases 2007; 196: 1447–1454
   PubMed Web of Science ®Google Scholar
• McMillan A. The management of difficult anogenital warts. Sexually Transmitted Diseases 1999; 75: 192–194
   Google Scholar
• Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24((Suppl 3))S35–S41.
   Google Scholar
• Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Current Medical Research and Opinion 2006; 22: 663–670.
   PubMed Web of Science ®Google Scholar
• Arveux P, Benard S, Bouee S, et al. Invasive cervical cancer treatment costs in France. Bulletin du Cancer 2007; 94: 219–224
   PubMed Web of Science ®Google Scholar
• Bergeron C, Breugelmans JG, Bouée S, et al. [Cervical cancer screening and associated treatment costs in France.]. Gynécologie, Obstétrique & Fertilité 2006; 34: 1036–1042, [in French]
   PubMedGoogle Scholar
• Monsonégo J, Breugelmans JG, Bouée S, et al. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Gynécologie, Obstétrique & Fertilité 2007; 35: 107–113, [in French].
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Available at: http://www.cdc.gov/nchs/about/otheract/icd9/abticd9.htm [accessed July 2007].
   Google Scholar
• Pirson M, Dramaix M, Leclercq P, et al. Analysis of cost outliers within APR-DRGs in a Belgian general hospital: two complementary approaches. Health Policy 2006; 76: 13–25
   Web of Science ®Google Scholar
• Analyse économique des coûts du cancer en France: impact sur la qualité de vie, prévention, dépistage, soins, recherche. «Etudes et expertises» éditée par l’Institut National du Cancer. Mars 2007
   Google Scholar
• National Institute for Statistics. Statistics Belgium. Available at: http://www.statbel.fgov.be [accessed July 2007]
   Google Scholar
• National Institute for Statistics. Available at: http://statbel.fgov.be/downloads/lfs1004-2004_fr.xls [accessed July 2007]
   Google Scholar
• National Institute for Health Insurance (INAMI/RIZIV). Available at: http://www.riziv.be [accessed July 2007]
   Google Scholar
• Castellsague X, De San José S, Aguado T, et al. HPV and cervical cancer in the world, 2007 report. Vaccine 2007; 25: C27–C219
   Google Scholar
• De Schrijver K. Epidemiologisch bulletin van de vlaamse gemeenschap, De epidemiologie van seksueel overdraagbare aandoeningen in belgië. NR 45 2003/3
   Google Scholar
• Belgian Cancer Registry Foundation. Available at: http://www.kankerregister.be/ [accessed December 2007]
   Google Scholar
• Available at: http://www.onssrszlss.fgov.be/Onssrsz/FR/Statistics/Brochures/Green/xls/rrn_2007_1_fr.xls [accessed July 2007]
   Google Scholar
• The National Centre for Screening Monitoring Fourth Report. Rivista dell’Associazione italiana di epidemiologia. Anno 30 (1) 2006 Supplemento 3
   Google Scholar
• Direction générale statistique et information économique. Population et ménages, Population totale et belge. 2004
   Google Scholar
• Wolstenholme JL, Whynes DK. Stage-specific treatment costs for cervical cancer in the United Kingdom. European Journal of Cancer 1998; 34: 1889–1893.
   PubMed Web of Science ®Google Scholar
• Thiry N, Lambert ML, Cleemput I, et al. Vaccination HPV pour la prévention du cancer du col de l’utérus en Belgique: Health Technology Assessment. KCE report 64B. Centre fédéral d’expertise des soins de santé (KCE), BrusselsBelgium 2007
   Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine 2007; 356: 1928–1943.
   PubMed Web of Science ®Google Scholar
• The FUTURE. II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine 2007; 356: 1915–1927
   Google Scholar
• Bergeron C, Largeron N, McAllister R, et al. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. International Journal of Technology Assessment in Health Care 2008; 24: 10–19
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Diseases 2007; 13: 28–41
   PubMed Web of Science ®Google Scholar